I wouldn’t be surprised to learn that GS/MS hold huge short positions

---

How would u know. Im the one living in a foreign country. Theres other banks offering financial instruments lil bro. Its a big world out here. HSBC, UBS, Societe Generale, Vonotoble, GS, Santander, etc. All offer options for American companies outside NYSE times

---

I finally bought calls. You are welcome bears Still hedged though. Fk you GS back to 500!

---

Cvna looking primed for a pump - JMP reiterated a $500 PT along with Jeffries and GS

---

$ALT looks primed for a breakout soon. Business update Nov 6. Late Breaking data poster Nov7 & oral presentation Nov11 @ AASLD nov 8-11. Obesity phase 3 ready. MASH resolution & fibrosis improvement best in class at 24 weeks once FDA accepts NITs any day. 48wk top line NITs & end of phase 2 FDA meeting minutes also anyday! Renewed bidding wars between pfizer and Novo for a phase 1 obesity asset the same day Lilly announced their glp1 is the best selling drug in the world.   GS has been suppressing this SP indiscriminately to protect the market for their customers NOVO & LILly. A huge risk reward value only days away from business updates AND key oral presentation at THE liver conference of the year. Now is the time to load up! The price has been pinned for months abd the short interest is 25.5%.    This drug pemvutide is next generation. Better quality weight loss than good diet and exercise(21% lean muscle loss vs 24% typical diet & exercise), great tolerability due to proprietary euport technology, 74 % liver fat reduction. 6% weight loss at 24 weeks. Its a healthy new liver for all drinkers with a side of weight loss.   The next generation GLP1 at $4.  Your damn right im holding!   Who doesn't love an underdog story right before their breakout 

---

Super manipulated by GS, who do work for NVO and LLY and want to protect them. Fuck them. The data are better, 25% SI, and p3-ready in MASH and obesity - right when FDA is making it easier. I hope they get burned hard. There are bidding wars for MASH/obesity drugs right now...they should know better.

---

$ALT is being manipulated by GS to protect NVO and LLY...but data are better. 25% SI. This could run hard when buyout rumors start, bidding wars in MASH/obesity drugs and a paucity of p3-ready options.

---

100% being shorted by GS to protect NVO and LLY. Data are better and heavily shorted.

---

$ALT looks primed for a breakout soon.  Late Breaking data & oral presentation @ AASLD nov 8-11.  Obesity phase 3 ready. MASH resolution & fibrosis improvement best in class at 24 weeks once FDA accepts NITs any day.   Renewed bidding wars between pfizer and Novo for a phase 1 obesity asset the same day Lilly announces their glp1 is the best selling drug in the world.   GS has been suppressing this SP indiscriminately to protect the market for their customers NOVO & LILly.  A huge risk reward value only days away from business updates  AND key oral presentation at THE liver conference of the year.  Now is the time to load up!  This drug pemvutide is next generation.  Better quality weight loss than good diet and we exercise(21% lean muscle loss vs 24% good diet & Exercise), great tolerability due to proprietary euport technology, 74 % liver fat reduction.  6% weight loss at 24 weeks. Its a healthy new liver for all drinkers with a side of weight loss.  

---

Currently holding $1M+, 60,000 shares of RKT... [https://www.reddit.com/r/wallstreetbets/comments/1oj76qk/rkt\_60k\_shares1m\_earnings\_tomorrow\_rkt\_price/](https://www.reddit.com/r/wallstreetbets/comments/1oj76qk/rkt_60k_shares1m_earnings_tomorrow_rkt_price/) BTIG and BoA have $25 targets for it, for '26. GS has $22, by '26.

---